Arvinas
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
ARVN Key Statistics
Stock Snapshot
Arvinas(ARVN) stock is priced at $13.72, giving the company a market capitalization of 879.46M. It carries a P/E multiple of -11.31.
On 2026-03-05, Arvinas(ARVN) stock traded between a low of $13.20 and a high of $13.97. Shares are currently priced at $13.72, which is +3.9% above the low and -1.8% below the high.
The Arvinas(ARVN)'s current trading volume is 1.04M, compared to an average daily volume of 983.8K.
During the past year, Arvinas(ARVN) stock moved between $5.90 at its lowest and $18.93 at its peak.
During the past year, Arvinas(ARVN) stock moved between $5.90 at its lowest and $18.93 at its peak.
ARVN News
Citi analyst Yigal Nochomovitz raised the firm’s price target on Arvinas (ARVN) to $18 from $15 and keeps a Buy rating on the shares. The firm updated the compa...
Analyst ratings
53%
of 19 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.